These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38864225)

  • 41. Identification and validation of a costimulatory molecule-related signature to predict the prognosis for uveal melanoma patients.
    Zhao M; Yu Y; Song Z
    Sci Rep; 2024 Apr; 14(1):9146. PubMed ID: 38644411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification and Prognostic Value Exploration of Cyclophosphamide (Cytoxan)-Centered Chemotherapy Response-Associated Genes in Breast Cancer.
    Du J; Dong Y; Li Y
    DNA Cell Biol; 2021 Nov; 40(11):1356-1368. PubMed ID: 34704810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 45. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of a 15-pseudogene based prognostic signature for predicting survival and antitumor immune response in breast cancer.
    Tan L; He X; Shen G
    Aging (Albany NY); 2020 Dec; 13(10):14499-14521. PubMed ID: 33378744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A ubiquitin-proteasome system-related signature to predict prognosis, immune infiltration, and therapy efficacy for breast cancer.
    Liu X; Wang M; Wang Q; Zhang H
    Immunol Res; 2024 Jun; 72(3):368-382. PubMed ID: 38036900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CX3CR1 Acts as a Protective Biomarker in the Tumor Microenvironment of Colorectal Cancer.
    Yue Y; Zhang Q; Sun Z
    Front Immunol; 2021; 12():758040. PubMed ID: 35140706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A four-gene signature in the tumor microenvironment that significantly associates with the prognosis of patients with breast cancer.
    Wang J; Yang Z; Zhang C; Ouyang J; Zhang G; Wu C
    Gene; 2020 Nov; 761():145049. PubMed ID: 32791092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of tumour microenvironment-related genes by TCGA database in rectal cancer.
    Li C; Liu T; Liu Y; Zhang J; Zuo D
    J Cell Mol Med; 2021 Jun; 25(12):5811-5822. PubMed ID: 33949771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene expression and DNA methylation analyses suggest that immune process-related ADCY6 is a prognostic factor of luminal-like breast cancer.
    Li W; Sang M; Hao X; Jia L; Wang Y; Shan B
    J Cell Biochem; 2020 Jul; 121(7):3537-3546. PubMed ID: 31886586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma.
    Peng Y; Yu H; Zhang Y; Qu F; Tang Z; Qu C; Tian J; Zong B; Wang Y; Ren H; Liu S
    Sci Rep; 2021 Sep; 11(1):17610. PubMed ID: 34475496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of a novel prognostic signature based on single-cell combined bulk RNA analysis in breast cancer.
    Xiao Y; Hu G; Xie N; Yin L; Pan Y; Liu C; Lou S; Zhu C
    J Gene Med; 2024 Feb; 26(2):e3673. PubMed ID: 38404059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
    Tang W; Xu F; Zhao M; Zhang S
    BMC Cancer; 2021 Oct; 21(1):1160. PubMed ID: 34715817
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ATP2C2 Has Potential to Define Tumor Microenvironment in Breast Cancer.
    Liu J; Wei Y; Wu Y; Li J; Sun J; Ren G; Li H
    Front Immunol; 2021; 12():657950. PubMed ID: 33936088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anoikis-related gene signatures can aid prognosis of lung adenocarcinoma.
    Mo G; Long X; Hu Z; Tang Y; Zhou Z
    Adv Clin Exp Med; 2024 Jul; 33(7):751-761. PubMed ID: 37767763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study.
    Huang Y; Chen L; Tang Z; Min Y; Yu W; Yang G; Zhang L
    Front Endocrinol (Lausanne); 2021; 12():774244. PubMed ID: 34867821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TCGA Database-Based Screening of Tumor Microenvironment Immunomodulators Related to Bladder Cancer Prognosis.
    Ye JN; Gan MP; Wu XL; Dong Z; Mai HH
    Ann Clin Lab Sci; 2024 May; 54(3):299-312. PubMed ID: 39048164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
    Liu J; Lu J; Li W
    Front Immunol; 2021; 12():738068. PubMed ID: 34630418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.